NetraMark Holdings Inc. (CSE:AIAI) is one of the latest new listings on the Canadian Securities Exchange, having previously traded as Nurosene Health. George Achilleos, CEO, stated: “This is reflective of the strategic shift that has been unfolding at our company and is a clear demonstration to our shareholders of our commitment to our corporate vision. It is our intent to be a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry. This is an important time for AI and there is a clear opportunity in the pharmaceutical industry, as outlined below.”
Additional Information:
Video Transcript:
NetraMark Holdings Inc. (CSE:AIAI) is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “AIAI” having previously traded as Nurosene Health,
This new name comes from NetraMark Corp, its wholly owned subsidiary acquired in October 2021.
George Achilleos, CEO, stated: “This is reflective of the strategic shift that has been unfolding at our company and is a clear demonstration to our shareholders of our commitment to our corporate vision. It is our intent to be a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry. This is an important time for AI and there is a clear opportunity in the pharmaceutical industry, as outlined below.”
From drug discovery through to FDA approval, developing a new medicine takes, on average, 10 to 15 years and costs approximately US$2.6 billion, with less than 12% of the candidate medicines successfully making it through the clinical trial process and receiving FDA approval.
One challenge facing the pharmaceutical industry is the inability to apply AI methods to small datasets and extract statistical significant insights that can be used to enrich future studies, as 95% of trials have less than 1,000 participants.
Netramark, founded in 2016 by Dr. Joseph Geraci Ph.D. to address the current gaps in the pharmaceutical industry, has developed proprietary algorithms that can change the way AI is used in this industry.
Following more than 5 years of development, the company launched NetraAI - a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously.
This allows NetraMark to use a variety of machine learning methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods.
The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.
Josh Spiegel, President, added: "I am excited about our capabilities to have a meaningful impact on an industry that our team has been a part of for many years. The name change certainly reflects the work we have done to develop NetraAI, a unique machine learning system that provides an intuitive interface for scientists to interact with multimodal small datasets to uncover connections related to efficacy, toxicity and placebo response.”
Bruce Campbell, President and Portfolio Manager of Stonecastle Investment Management has joined us today to give us some insight into NetraMark, and why it has a place in his portfolio. Welcome Bruce.
The shares are trading at $0.40.
For more information, please visit the company’s websites at www.nurosene.com and www.NetraMark.com, or email investors@nurosene.com.
